Mr. Tuttle continued, "Our Pharmaceutical Research Services group performed work for six pharmaceutical companies so far this year, and we signed several new contracts with these and other new partners which will result in continued growth for this division. We are also in the process of increasing resources in our clinical molecular diagnostics lab to further drive growth similar to what we have been experiencing for this business over the last few quarters. Finally, we expect to realize the full impact of the ongoing consolidations and other cost reduction by the fourth quarter of the year. This is a very exciting time for the company as we enjoy the results of our refocusing on strong financial performance in our traditional mutation discovery tools business and substantial growth in our diagnostics laboratory business and Pharmaceutical Research Services business."
Company management will discuss second quarter 2007 financial results via teleconference on Tuesday, August 14, 2007 at 5:00 p.m. Eastern Time. To access the call via telephone, dial 800-896-8445 or 785-830-1916. The company will also host a live broadcast of the call over the Internet. To listen to the webcast, investors should log on to the company's Investor Relations web page at http://www.transgenomic.com/events.asp?id=6 and follow the instructions provided. An archived recording of the conference call will be available and can be accessed via the web using the same link listed above for 14 days after the call. Investors can also listen to a replay via telephone until 11:59 p.m. Eastern Time on Tuesday, August 28, 2007. Simply dial 800-839-9881 or 402-220-3100 from any telephone.
About Transgenomic: A decade of discovery 1997 - 2007
Transgenomic is a global biotechnology company that provides unique
products and services for automated high sensitivity genet
|SOURCE Transgenomic, Inc.|
Copyright©2007 PR Newswire.